Compare SPRY & FRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | FRA |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.7M | 395.1M |
| IPO Year | 2020 | 2003 |
| Metric | SPRY | FRA |
|---|---|---|
| Price | $4.05 | $9.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 177.5K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.06% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $52.57 | N/A |
| Revenue Next Year | $45.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.81 | $9.98 |
| 52 Week High | $13.15 | $12.71 |
| Indicator | SPRY | FRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 23.57 |
| Support Level | $3.91 | N/A |
| Resistance Level | $4.60 | $11.18 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 27.26 | 34.67 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
Blackrock Floating Rate Inc Stra Fd Inc is a closed-end management investment company. Its investment objective is to provide shareholders with high current income and such preservation of capital as is consistent with investment in a diversified, leveraged portfolio consisting of floating rate debt securities and instruments. The Fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its managed assets in floating rate debt securities, including floating or variable rate debt securities that pay interest at rates that adjust whenever a specified interest rate changes and/or which reset on predetermined dates (such as the last day of a month or calendar quarter).